SG11201705378RA - Methods of treating retinal diseases - Google Patents

Methods of treating retinal diseases

Info

Publication number
SG11201705378RA
SG11201705378RA SG11201705378RA SG11201705378RA SG11201705378RA SG 11201705378R A SG11201705378R A SG 11201705378RA SG 11201705378R A SG11201705378R A SG 11201705378RA SG 11201705378R A SG11201705378R A SG 11201705378RA SG 11201705378R A SG11201705378R A SG 11201705378RA
Authority
SG
Singapore
Prior art keywords
methods
retinal diseases
treating retinal
treating
diseases
Prior art date
Application number
SG11201705378RA
Other languages
English (en)
Inventor
Eyal Banin
Benjamin Eithan Reubinoff
Osnat Bohana-Kashtan
Nir Netzer
Charles Sherard Irving
Original Assignee
Cell Cure Neurosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56284392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201705378R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cell Cure Neurosciences Ltd filed Critical Cell Cure Neurosciences Ltd
Publication of SG11201705378RA publication Critical patent/SG11201705378RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/00727—Apparatus for retinal reattachment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
SG11201705378RA 2014-12-30 2015-04-30 Methods of treating retinal diseases SG11201705378RA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462097753P 2014-12-30 2014-12-30
US201562116972P 2015-02-17 2015-02-17
US201562116980P 2015-02-17 2015-02-17
PCT/IL2015/050456 WO2016108219A1 (en) 2014-12-30 2015-04-30 Methods of treating retinal diseases

Publications (1)

Publication Number Publication Date
SG11201705378RA true SG11201705378RA (en) 2017-08-30

Family

ID=56284392

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201705378RA SG11201705378RA (en) 2014-12-30 2015-04-30 Methods of treating retinal diseases

Country Status (18)

Country Link
US (2) US20180008458A1 (ko)
EP (1) EP3240612B1 (ko)
JP (4) JP2018501281A (ko)
KR (2) KR102359257B1 (ko)
CN (3) CN114533761A (ko)
AU (3) AU2015373111B2 (ko)
BR (1) BR112017014332A2 (ko)
CA (2) CA3175175A1 (ko)
DK (1) DK3240612T3 (ko)
EA (1) EA201791518A1 (ko)
ES (1) ES2843626T3 (ko)
HK (1) HK1246179A1 (ko)
IL (1) IL253244B2 (ko)
MX (1) MX2017008818A (ko)
PH (1) PH12017501217A1 (ko)
SG (1) SG11201705378RA (ko)
WO (1) WO2016108219A1 (ko)
ZA (1) ZA201704359B (ko)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102073730B1 (ko) 2009-11-17 2020-02-05 아스텔라스 인스티튜트 포 리제너러티브 메디슨 인간 ｒｐｅ 세포의 생산 방법 및 인간 ｒｐｅ 세포의 제약 제제
KR20170115514A (ko) 2014-12-30 2017-10-17 셀 큐어 뉴로사이언시스 리미티드 Rpe 세포 집단 및 이를 생성하는 방법
CA3175175A1 (en) 2014-12-30 2016-07-07 Cell Cure Neurosciences Ltd. Methods of treating retinal diseases
WO2016108240A1 (en) 2014-12-30 2016-07-07 Cell Cure Neurosciences Ltd. Assessing retinal pigment epithelial cell populations
ES2865024T3 (es) 2015-07-29 2021-10-14 Hadasit Med Res Service Producción a gran escala de células de epitelio pigmentario retiniano
WO2017021972A1 (en) * 2015-08-05 2017-02-09 Cell Cure Neurosciences Ltd. Preparation of photoreceptors for the treatment of retinal diseases
WO2018170494A1 (en) 2017-03-16 2018-09-20 Bio Time, Inc. Methods for measuring therapeutic effects of retinal disease therapies
CA3071648A1 (en) 2017-07-31 2019-02-07 Biotime, Inc. Compositions and methods for restoring or preventing loss of vision caused by disease or traumatic injury
JP2021509110A (ja) * 2017-12-29 2021-03-18 セル キュア ニューロサイエンシズ リミテッド 網膜色素上皮細胞組成物
CN108795864B (zh) * 2018-05-24 2021-08-24 中山大学中山眼科中心 一种利用人诱导多能干细胞获得富含视锥及视杆细胞的类视网膜组织的方法
US10264436B1 (en) * 2018-05-29 2019-04-16 Link Labs, Inc. BLE networking systems and methods providing central and peripheral role reversal with independent peripheral network connectivity
US20220033826A1 (en) * 2018-08-31 2022-02-03 University Of Florida Research Foundation, Incorporated Adeno-associated viral vectors for the treatment of best disease
JP2022532411A (ja) * 2019-05-15 2022-07-14 ノヴォ ノルディスク アー／エス ヒト多能性幹細胞から眼野前駆細胞を得るための方法
WO2022049259A1 (en) * 2020-09-03 2022-03-10 Curebiotech Gmbh Pigment epithelium-derived factor (pedf) for use in treatment of macular degeneration or choroidal neovascularisation
EP3964227A1 (en) * 2020-09-08 2022-03-09 Curebiotec GmbH Method for the treatment of a disease using pigment epithelium-derived factor (pedf)
KR102633321B1 (ko) * 2021-05-11 2024-02-05 연세대학교 산학협력단 노인성 황반변성의 예방 또는 치료를 위한 약학 조성물
CN115212233A (zh) * 2022-08-26 2022-10-21 北京市眼科研究所 用于治疗视网膜相关疾病的组合物、试剂盒及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
CA2684460C (en) 2007-04-18 2017-01-03 Hadasit Medical Research Services & Development Limited Stem cell-derived retinal pigment epithelial cells
IL292561A (en) * 2007-10-12 2022-06-01 Astellas Inst For Regenerative Medicine Improved methods of rpe cell production and rpe cell preparations
KR101025880B1 (ko) * 2008-10-23 2011-03-30 공희숙 성체 줄기세포를 이용한 인슐린 분비세포로의 분화 유도방법
KR102073730B1 (ko) * 2009-11-17 2020-02-05 아스텔라스 인스티튜트 포 리제너러티브 메디슨 인간 ｒｐｅ 세포의 생산 방법 및 인간 ｒｐｅ 세포의 제약 제제
CA3178098A1 (en) * 2011-11-14 2013-05-23 Astellas Institute For Regenerative Medicine Pharmaceutical preparations of human rpe cells and uses thereof
US9850463B2 (en) * 2012-02-01 2017-12-26 The Regents Of The University Of California Methods of culturing retinal pigmented epithelium cells, including xeno-free production, RPE enrichment, and cryopreservation
US20150112282A1 (en) * 2012-04-09 2015-04-23 Industry-Academic Cooperation Foundation, Yonsei University Hollow microneedle and subretinal syringe for subretinal injection or extraction
JP6426110B2 (ja) 2013-02-01 2018-11-21 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 人口多能性幹細胞（ｉｐｓｃ）由来の網膜色素上皮（ｒｐｅ）細胞を生成するための方法
MX2016007671A (es) * 2013-12-11 2016-10-14 Pfizer Ltd Metodo para producir celulas del epitelio pigmentario retiniano.
CA3175175A1 (en) 2014-12-30 2016-07-07 Cell Cure Neurosciences Ltd. Methods of treating retinal diseases
KR20170115514A (ko) 2014-12-30 2017-10-17 셀 큐어 뉴로사이언시스 리미티드 Rpe 세포 집단 및 이를 생성하는 방법
WO2016108240A1 (en) 2014-12-30 2016-07-07 Cell Cure Neurosciences Ltd. Assessing retinal pigment epithelial cell populations
KR101982801B1 (ko) * 2015-10-28 2019-05-30 서울대학교 산학협력단 망막색소상피 분화 유도용 조성물

Also Published As

Publication number Publication date
EP3240612B1 (en) 2020-12-23
EA201791518A1 (ru) 2017-10-31
KR20170120583A (ko) 2017-10-31
AU2021229196A1 (en) 2021-10-07
JP2018501281A (ja) 2018-01-18
KR102514912B1 (ko) 2023-03-27
IL253244A0 (en) 2017-08-31
CN107427534A (zh) 2017-12-01
IL253244B1 (en) 2023-05-01
PH12017501217A1 (en) 2018-01-29
AU2015373111B2 (en) 2021-06-24
IL253244B2 (en) 2023-09-01
WO2016108219A1 (en) 2016-07-07
US20230028133A1 (en) 2023-01-26
JP2020143137A (ja) 2020-09-10
EP3240612A4 (en) 2018-06-13
BR112017014332A2 (pt) 2018-01-02
JP2024023611A (ja) 2024-02-21
CA3175175A1 (en) 2016-07-07
HK1246179A1 (zh) 2018-09-07
KR102359257B1 (ko) 2022-02-07
ES2843626T3 (es) 2021-07-19
AU2023255009A1 (en) 2023-11-16
CA2972700A1 (en) 2016-07-07
CN114533761A (zh) 2022-05-27
EP3240612A1 (en) 2017-11-08
MX2017008818A (es) 2018-03-14
KR20220020422A (ko) 2022-02-18
CN114469998A (zh) 2022-05-13
DK3240612T3 (da) 2021-01-18
JP2022125160A (ja) 2022-08-26
US20180008458A1 (en) 2018-01-11
ZA201704359B (en) 2018-08-29
AU2015373111A1 (en) 2017-07-13

Similar Documents

Publication Publication Date Title
IL283561B (en) Methods for treating eye diseases
HK1246179A1 (zh) 治療視網膜疾病的方法
HK1231417A1 (zh) 用於治療眼科疾病和障礙的化合物
GB201701673D0 (en) Methods of well treatment
PT3212233T (pt) Terapia combinada para o tratamento de doenças
IL246791A0 (en) Compositions and methods for treating eye diseases
FI3851537T3 (fi) Hyperbilirubinemian hoito
ZA201807084B (en) Methods of treatment of cholestatic diseases
HK1245127A1 (zh) 治療腦疾病的方法和組合物
HK1258994A1 (zh) 用於疾病治療的方法
HK1247818A1 (zh) 治療疾病的方法
GB201410116D0 (en) Method of treatment
IL251769A0 (en) Methods for treating eye conditions
GB201416832D0 (en) Methods of treatment
GB201412578D0 (en) Treatment of neurological diseases
HK1243937A1 (zh) 治療疾病的方法
IL259381B (en) Miravegron for the treatment of retinal diseases
PL3302463T3 (pl) Zastosowanie 3 deoksyantocyjanidyn w leczeniu chorób oczu
GB201512139D0 (en) Methods of treatment
PT3851537T (pt) Tratamento da hiperbilirrubinemia
GB201414023D0 (en) Treatment of autoimmune diseases
GB201421980D0 (en) Method of treatment
GB201421982D0 (en) Method of treatment
GB201415331D0 (en) Method of treatment
GB201414780D0 (en) Method Of Treatment